News Headlines Article

The fix is in: Portola blood-thinner antidote moves into late-stage trial
San Francisco Business Times

An experimental universal blood-thinner antidote, aimed at potentially millions of patients on drugs that prevent life-threatening blood clots, pushed into the first of several small Phase III trials by Portola Pharmaceuticals Inc. The initial studies test South San Francisco-based Portola’s (NASDAQ: PTLA) andexanet alfa with Eliquis, an FDA-approved Factor Xa inhibitor from Bristol-Myers Squibb Co. (NYSE: BMY) and Pfizer Inc. (NYSE: PFE).

Commands